Dannex Ayrton Starwin Plc has secured regulatory approval to delay publication of its full-year 2025 audited financial statements, with the Securities and Exchange Commission (SEC) granting the listed pharmaceutical manufacturer an extension to submit the accounts by April 30, 2026.
The disclosure, signed by the company’s Chief Finance Officer and dated March 27, 2026, informed shareholders, customers, and the investing public that the new deadline replaces the original submission schedule for statements covering the year ended December 31, 2025.
The company did not state reasons for the delay in the notice but said it appreciates the continued understanding and support of its stakeholders.
Dannex Ayrton Starwin had previously released unaudited results for 2025 showing a full-year net profit of GH¢14.3 million and revenue growth of 9.8 percent to GH¢190.2 million, a strong finish that contrasted with mid-year losses driven by currency pressures and rising operating costs. The audited statements, when published, will provide the formal, independently verified version of those figures.
The company, which operates as Ghana’s largest pharmaceutical manufacturer following the 2020 merger of Dannex Limited, Ayrton Drug Manufacturing Limited, and Starwin Products Limited, manufactures and distributes tablets, capsules, syrups, creams, disinfectants, and veterinary products across West Africa.
Dannex Ayrton Starwin is listed on the Ghana Stock Exchange (GSE) under the ticker DASPHARMA. Investors tracking the stock will now look to the end of April for the audited confirmation of the company’s 2025 financial position.
